News roundup Thursday, March 14

» Clinical effects observed with Alligator's 4-1BB agonist
» Dicot's phase I study completes recruitment
» BioStock Investor Pitch: Cancel
» Curasight cancels issue and evaluates alternative financing
» Lipum strengthens its finances ahead of Phase II and moves production home

Read BioStock's weekly newsletter for v.10 here.

Latest news of the day

Bone support announces that CERAMENT G receives market approval in the United States. Read more.

Bavarian Nordic receives approval in Switzerland for smallpox and mumps vaccines. Read more.

AstraZeneca acquires Amolyt Pharma and is expanding its pipeline in late-stage rare diseases. Read more.

Last day for trading in warrants of series TO3 in Cereno Scientific is today, March 14th. Read more.

Atrogy announces positive clinical data from first-in-class insulin-independent treatment for type II diabetes. Read more.

Q-line has presented results for ASTs vid AMCLI. Read more.

Orexo has issued senior secured social bonds of SEK 500 million and announces the results of the repurchase offer regarding its existing bonds. Read more.

Bioservo informs about study showing improved hand function with Carbonhand. Read more.

Faron will hold a webcast on March 19 regarding the latest results from the Phase I part of the BEXMAB study with Bexmarilimab. Read more.

Carbiotix increases evaluation activities for prebiotics and technology partners. Read more.

Anocca licenses gene editing technology from EmendoBio Inc. Read more.

Last day for trading BTU in Coegin Pharma is March 18th. Read more.

Oblique Therapeutics announces the outcome of the rights issue. Read more.

Gentian Diagnostics announces that new KDIGO guidelines recommend increased use of cystatin C. Read more.

Thor Medical receives contributions from Innovation Norway for lab and pilot facilities on Herøya. Read more.

NextCell establishes the subsidiary QVance to meet Nordic demand for quality analyses. Read more.

Canadian healthcare provider chooses Sects cloud service for increased cybersecurity and more efficient image management. Read more.

Proby strengthens its brand position and expands in the Nordic region. Read more.

Getinge highlights Sanquins role in promoting blood supply and medical research. Read more.

AlzeCure attending the event on March 21st. Read more.

SoftOx Solutions publishes financial calendar. Read more.

New research shows that it is possible to increase bone formation around surgical implants in patients with osteoporosis. Read more.

Communiqués

Genmab  Össur

Voices

Arjo  Faron Pharmaceuticals  Oncopeptides